On November 1, 2023, VYNE Therapeutics Inc. closed the transaction.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.54 USD | +1.60% | +8.09% | +9.01% |
Apr. 04 | Transcript : VYNE Therapeutics Inc. - Special Call | |
Feb. 29 | VYNE Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.01% | 35.25M | |
+25.87% | 661B | |
+26.74% | 566B | |
-6.41% | 352B | |
+20.55% | 332B | |
+3.66% | 283B | |
+14.28% | 231B | |
+5.16% | 200B | |
-8.92% | 195B | |
-5.10% | 145B |
- Stock Market
- Equities
- VYNE Stock
- News VYNE Therapeutics Inc.
- VYNE Therapeutics Inc. announced that it has received $88.151509 million in funding from Acorn Bioventures, Parkman Healthcare Partners LLC, Soleus Capital, Surveyor Capital Management, Palo Alto Investors LP and other investors